Biktarvy
Patients prefer ViiV’s injectable HIV medication, according to a Switch research
SG Tylor
When ViiV Healthcare and Johnson & Johnson introduced their once-monthly injectable HIV treatment Cabenuva in 2021, they anticipated that patients ...
Biktarvy Continues to Show Safety and Efficacy Across Diverse Populations Impacted by the Global HIV Epidemic: Updated Findings from IAS 2023
SG Tylor
Source – Gilead Gilead Sciences, has released the results of several studies further solidifying Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir ...
